Wolfe Research initiated coverage of Crispr Therapeutics with a Peer Perform rating. The company’s stock price suggests that Casgevy performance is priced in, the analyst tells investors in a research note. Wolfe adds that it sees reimbursement hurdles, with some offset from strong interest from physicians and patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics Secures Funding Through Share Issuance
- Crispr Therapeutics announces $280M registered diect offering
- Crispr Therapeutics’ Gene Therapy Wins EU Approval
- European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
- Is CRSP a Buy, Before Earnings?
